Insulet (NASDAQ:PODD) Price Target Raised to $305.00

Insulet (NASDAQ:PODDFree Report) had its price target boosted by Wells Fargo & Company from $290.00 to $305.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

PODD has been the topic of a number of other reports. BTIG Research increased their price target on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. Piper Sandler increased their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Morgan Stanley raised their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Citigroup upped their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $267.44.

Read Our Latest Report on Insulet

Insulet Price Performance

Shares of PODD stock opened at $269.34 on Wednesday. The firm’s 50 day moving average price is $251.37 and its two-hundred day moving average price is $220.02. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $18.89 billion, a PE ratio of 46.12, a PEG ratio of 4.18 and a beta of 1.21. Insulet has a 52-week low of $160.19 and a 52-week high of $279.77.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Insulet in the second quarter valued at about $32,000. UMB Bank n.a. grew its position in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its stake in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares in the last quarter.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Stories

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.